Home » Posts tagged with » SARS-CoV-2
UAE approves Russia-made Sputnik V Covid-19 vaccine

UAE approves Russia-made Sputnik V Covid-19 vaccine

The Russian Direct Investment Fund (RDIF) said that the Russian Sputnik V Covid-19 vaccine has been authorized for use by the UAE Ministry of Health and Prevention (MOHAP) in the country for providing protection against the SARS-CoV-2 virus. According to the Russian sovereign wealth fund, the Sputnik V vaccine was registered under the emergency use […]

Thermo Fisher to acquire molecular diagnostic company Mesa Biotech for up to $500m

Thermo Fisher Scientific has agreed to acquire California-based point-of-care molecular diagnostic company Mesa Biotech in a deal worth up to $500 million. The consideration includes nearly $450 million in cash and an additional amount of up to $100 million, which will be subject to Mesa Biotech achieving certain milestones post-acquisition. The molecular diagnostic company has […]

Continue reading …
Swissmedic authorizes use of BNT162b2 Covid-19 vaccine from Pfizer, BioNTech

Swissmedic, the Swiss Agency for Therapeutic Products, has authorized the use of the BNT162b2 Covid-19 vaccine from US pharma giant Pfizer and German biotech company BioNTech. The Swiss pharma regulator said that as per the data it has assessed, the level of protection afforded seven days following the second dose of the mRNA vaccine is […]

Continue reading …
US FDA authorizes Moderna Covid-19 vaccine mRNA-1273

Moderna Covid-19 vaccine : The US Food and Drug Administration (FDA) has given emergency use authorization (EUA) for mRNA-1273, the messenger RNA (mRNA) Covid-19 vaccine candidate of Moderna. The FDA authorization is for the use of mRNA-1273 in individuals aged 18 years and more for the prevention of Covid-19 caused by severe acute respiratory syndrome […]

Continue reading …
Pfizer and BioNTech secure FDA EUA for BNT162b2 Covid-19 vaccine

BNT162b2 FDA EUA : Pfizer and BioNTech have been granted emergency use authorization (EUA) from the US Food and Drug Administration (FDA) for BNT162b2, their Covid-19 mRNA vaccine. BNT162b2 has been authorized by the FDA for its use in the prevention of Covid-19 in individuals aged 16 years or more. Pfizer and BioNTech will look […]

Continue reading …
Pfizer, BioNTech get Canadian approval for BNT162b2 Covid-19 vaccine

US pharma giant Pfizer and German biotech company BioNTech have bagged Health Canada approval for their BNT162b2 Covid-19 vaccine. The BNT162b2 vaccine has been authorized to be used in Canada under the regulator’s Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to Covid-19. Canada has now joined the UK […]

Continue reading …
Bamlanivimab Covid-19 drug candidate : Lilly, UnitedHealth Group join forces for pragmatic study

Eli Lilly and Company (Lilly) has entered into a partnership with managed care company UnitedHealth Group to carry out a pragmatic study of bamlanivimab (LY-CoV555) in high-risk, Covid-19 infected individuals. Recently, bamlanivimab was granted emergency use authorization (EUA) from the US Food and Drug Administration for the treatment of Covid-19 patients having mild to moderate […]

Continue reading …
India approves Saragene COVID-19 2-gene multiplex RT-PCR test

CoSara Diagnostics has secured clearance from the Indian Central Drugs Standard Control Organization (CDSCO) to manufacture and sell its Saragene COVID-19 2-gene multiplex RT-PCR test. The approval allows the Saragene COVID-19 2-gene multiplex RT-PCR test to be used as an in vitro diagnostic (IVD) in the qualitative detection of the SARS-CoV-2 virus that causes Covid-19. […]

Continue reading …
BNT162b2 Covid-19 vaccine candidate more than 90% effective in phase 3 trial, say Pfizer and BioNTech

Pfizer and BioNTech announced that the BNT162b2 mRNA-based vaccine candidate has been shown to be more than 90% effective in the prevention of Covid-19 in participants of a phase 3 trial who were not previously exposed to the SARS-CoV-2 infection. The data is based on the first interim efficacy analysis from the phase 3 clinical […]

Continue reading …
AstraZeneca to advance AZD7442 into phase 3 Covid-19 trials

AstraZeneca said that AZD7442, which is being developed for the prevention and treatment of Covid-19, will move into two phase 3 clinical trials. AZD7442 is a combination of a couple of monoclonal antibodies (mAbs) extracted from convalescent patients with SARS-CoV-2 infection. It will be assessed in more than 6,000 participants at sites in and outside […]

Continue reading …
Page 1 of 3123